AstraZeneca announces healthy profits, dismisses CEO speculation
639647
Troubled Anglo-Swedish drugs giant AstraZeneca reported a 15.7-percent rise in profits for 2004, despite controversy over key products and amid speculation about the future of its chief executive.
594552
LONDON (CBS.MW) -- Pharmaceutical maker AstraZeneca (UK:AZN) (AZN) said it&#39;s investing 75 million British pounds ($139 million) in cash for a 19.9 percent stake in UK biotech group Cambridge Antibody Technology (UK:CAT) (CATG) as part of a five year, R&amp;D
574773
A newspaper advertisement for AstraZeneca Plc's cholesterol drug Crestor that touts patient safety is misleading and should no longer be published, regulators warned in a letter released Wednesday.
684039
BASEL, Switzerland  - Net profits at Novartis AG  rose by a lower-than-expected 15 percent last year as  restructuring costs weighed, the company reported on Thursday,  but the world's sixth biggest drugmaker said it expects record  sales and profits in 2005.
406531
Cambridge Antibody Technology has announced an alliance with pharmaceutical giant AstraZeneca after posting a slightly narrower annual loss before tax.
63381
Biotech giant Amgen Inc. reported Thursday that its fourth-quarter profits rose, topping analysts' estimates, despite government warnings about the safety of its popular anemia drugs.
419018
Health-care plan provider UnitedHealth Group Inc. on Monday reaffirmed its previous outlook for 2004 earnings of at least $3.92 per share, up 32 percent or more from the $2.
698
Sir Tom McKillop, the chief executive of AstraZeneca, will this week launch a charm offensive to reassure investors that the pharmaceutical group&#39;s prospects remain strong
579427
Sanofi-Aventis posted higher than expected fourth-quarter profits on Tuesday and predicted more growth for 2007, but a further delay in its key new anti-obesity drug Acomplia hit the shares.
346497
An FDA review of AstraZeneca Plc&#39;s (AZN.L: Quote, Profile, Research) (AZN.N: Quote, Profile, Research) Exanta questioned the experimental drug&#39;s
298049
The pharmaceutical company reported a 5 percent increase in fourth-quarter earnings but said growth would slow this year as generic competition picked up.
60402
Biogen Idec Inc. BIIB.O on Monday  reported a quarterly profit on sales of its multiple sclerosis  and cancer drugs versus a year-ago loss, but said costs will  rise in 2005, trimming earnings growth.
323016
German drugs and chemicals group Merck has reported quarterly earnings that have easily beaten forecasts thanks to strong sales of cancer drug Erbitux and a one-off payment for an alcoholism drug.
113293
AstraZeneca was dealt a blow yesterday when an official from the US&#39;s drugs watchdog questioned whether one of its key products ought to be sold in the world&#39;s largest pharmaceuticals market.
330312
A federal judge in Massachusetts ruled on Thursday that pharmaceutical companies AstraZeneca, Bristol-Myers Squibb and Schering-Plough Corp. subsidiary Warrick Pharmaceuticals falsely marked up U.S. drug prices at various times through 2003.
627881
European shares retreated on Wednesday as AstraZeneca's business update disappointed investors and on nagging concerns that soaring oil prices will hurt the quality of future earnings.
376389
Blue chips ended the session slightly higher, reversing earlier losses in a late rally, boosted by healthy gains in AstraZeneca, strong earnings from Nokia and as Wall Street came off initial lows, dealers said.